Journal Watch · JAMA Oncology · 2026

Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320).

Cautious patient selection and further investigation to identify those who may benefit without undue risk are required.<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT04462276.

Bozorgmehr F, Chung I, Behnisch R et al.JAMA Oncology4 min readPharma relevance 75/100

DOI: 10.1001/jamaoncol.2026.2330PMID: 42424047Study type: randomised / controlled clinical trial

TL;DR

Cautious patient selection and further investigation to identify those who may benefit without undue risk are required.<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT04462276.

Key findings

  • Safety analysis revealed predominance of infection and respiratory disorder-related SAEs, possibly facilitated by a depletion of lymphocytes observed specifically in patients after TRT, and by a lower single breath diffuse capacity of the lungs for carbon monoxide in patients with fatal AEs in arm A.
  • No further risk factors were identified, given that baseline characteristics were well balanced between both arms and between patients with and without SAEs, including fatal SAEs.<h4>Conclusions and relevance</h4>In this randomized clinical trial, TRT combined with immunotherapy increased toxic effects in unselected patients with ES-SCLC without survival benefit, presumably due to radiation-induced lymphocyte depletion facilitating infections.
  • Cautious patient selection and further investigation to identify those who may benefit without undue risk are required.<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT04462276.

Numbers at a glance (from the abstract)

95%61.3%18.2%19.4%3.0%P = .34P = .85P < .001P = .04

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Data were analyzed from April 2025 to April 2026.<h4>Interventions</h4>Randomized (1:1) to either atezolizumab maintenance combined with consolidative TRT (30 Gy in 10 fractions) (arm A) or atezolizumab maintenance alone (arm B).<h4>Main outcome and measure</h4>OS (time from randomization to death due to any cause).<h4>Results</h4>Of 96 patients assessed for eligibility, 68 patients were randomized; recruitment was prematurely terminated due to safety concerns. Median OS in the combination arm was numerically shorter compared to atezolizumab only (6.7 months [95% CI, 5.1-9.0] vs 13.4 months [95% CI, 10.7-17.5]; HR, 1.55 [95% CI, 0.90-2.69]; P = .34), while median PFS was similar (2.4 months [95% CI, 1.3-3.9] vs 2.6 months [95% CI, 1.2-3.9]; HR, 0.92 [95% CI, 0.54-1.55]; P = .85). TRT plus atezolizumab was accompanied by higher frequency of severe adverse events (SAEs) (19 patients [61.3%] vs 6 patients [18.2%]; P < .001) and fatal outcomes (6 patients [19.4%] vs 1 patient [3.0%]; P = .04).

Full abstract (original)

Background: <h4>Importance</h4>Chemoimmunotherapy followed by immunotherapy maintenance is the standard first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), yet data regarding efficacy and safety of consolidative thoracic radiotherapy (TRT) are lacking.<h4>Objective</h4>To determine whether combining consolidative TRT with immunotherapy maintenance in ES-SCLC is safe and improves patients' overall survival (OS) and progression-free survival (PFS).<h4>Design, settings, and participants</h4>This was a multicenter open-label phase 2 randomized clinical trial recruiting patients from September 2020 to August 2022 in Germany and Austria, with the last follow-up visit in September 2024. Eligible patients had ES-SCLC with at least stable disease after induction chemoimmunotherapy (carboplatin-etoposide-atezolizumab). Although the database was locked in April 2025, a post hoc survival update was performed in April 2026.

What they did: Data were analyzed from April 2025 to April 2026.<h4>Interventions</h4>Randomized (1:1) to either atezolizumab maintenance combined with consolidative TRT (30 Gy in 10 fractions) (arm A) or atezolizumab maintenance alone (arm B).<h4>Main outcome and measure</h4>OS (time from randomization to death due to any cause).<h4>Results</h4>Of 96 patients assessed for eligibility, 68 patients were randomized; recruitment was prematurely terminated due to safety concerns. Median OS in the combination arm was numerically shorter compared to atezolizumab only (6.7 months [95% CI, 5.1-9.0] vs 13.4 months [95% CI, 10.7-17.5]; HR, 1.55 [95% CI, 0.90-2.69]; P = .34), while median PFS was similar (2.4 months [95% CI, 1.3-3.9] vs 2.6 months [95% CI, 1.2-3.9]; HR, 0.92 [95% CI, 0.54-1.55]; P = .85). TRT plus atezolizumab was accompanied by higher frequency of severe adverse events (SAEs) (19 patients [61.3%] vs 6 patients [18.2%]; P < .001) and fatal outcomes (6 patients [19.4%] vs 1 patient [3.0%]; P = .04).

Results & conclusions: Safety analysis revealed predominance of infection and respiratory disorder-related SAEs, possibly facilitated by a depletion of lymphocytes observed specifically in patients after TRT, and by a lower single breath diffuse capacity of the lungs for carbon monoxide in patients with fatal AEs in arm A. No further risk factors were identified, given that baseline characteristics were well balanced between both arms and between patients with and without SAEs, including fatal SAEs.<h4>Conclusions and relevance</h4>In this randomized clinical trial, TRT combined with immunotherapy increased toxic effects in unselected patients with ES-SCLC without survival benefit, presumably due to radiation-induced lymphocyte depletion facilitating infections. Cautious patient selection and further investigation to identify those who may benefit without undue risk are required.<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT04462276.

Abstract © the authors / JAMA Oncology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1001/jamaoncol.2026.2330 · PubMed 42424047.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking JAMA Oncology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this JAMA Oncology study find?

Cautious patient selection and further investigation to identify those who may benefit without undue risk are required.<h4>Trial registration</h4>ClinicalTrials.gov Identifier: NCT04462276.

What type of study is this?

It is a randomised / controlled clinical trial, published in JAMA Oncology in 2026. Data were analyzed from April 2025 to April 2026.<h4>Interventions</h4>Randomized (1:1) to either atezolizumab maintenance combined with consolidative TRT (30 Gy in 10 fractions) (arm A) or atezolizumab maintenance alone (arm B).<h4>Main outcome and measure</h4>OS (time from randomization to death due to any cause).<h4>Results</h4>Of 96 patients assessed for eligibility, 68 patients were randomized; recruitment was prematurely terminated due to safety concerns.

Where can I read the original paper?

The original is at the publisher via DOI 10.1001/jamaoncol.2026.2330. PubMed ID: 42424047. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Bozorgmehr F, Chung I, Behnisch R et al.. Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320).. JAMA Oncology (2026). DOI: 10.1001/jamaoncol.2026.2330.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/consolidative-thoracic-radiotherapy-with-atezolizumab-maintenance-in-ext-262330/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides